Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

ThinkEquity Cuts Idenix to Sell from Accumulate

ThinkEquity Partners cut its investment recommendation on Idenix Pharmaceuticals (IDIX) to sell from accumulate, citing lack of conviction in the company's products.

Analyst Andrew McDonald said he doesn't think Idenix's drugs are going to sell and will be of no benefit to humanity. He says investors know that he has deep domain expertise in hepatitis C, so he's not surprised to see downgrade pressure in the stock price this morning. He says lots of people have questioned the performance of hepatitis drugs, but they'd been in Idenix's stock due to the expected $525 million opt-in from Novartis (NVS). He says that a secondary offering/financing ahead of this opt-in causes him grave concern. He cut his price target on the stock to $17.

blog comments powered by Disqus